코오롱생명과학
Financials
Valuation Metrics
코오롱생명과학's Market Cap is ₩1831B. At end of 2025 it was ₩6768B. Ranked #904 of 2,421 in KR market (top 37%), #430 of 1,640 on KOSDAQ (top 26%), #99 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 43%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 183.14B KRW | KR#904/2,421 Sec#99/231 |
| Revenue | 211.44B KRW | KR#997/2,421 Sec#57/231 |
| Net Income | 34.63B KRW | KR#521/2,421 Sec#32/231 |
| Total Assets | 1.08T KRW | KR#460/2,421 Sec#26/231 |
| Net Assets | 696.93B KRW | KR#389/2,421 Sec#25/231 |
| Employees | 444 | KR#552/2,421 Sec#44/231 |
| Value | ||
| P/E | 5.29x | KR#382/2,421 Sec#14/231 |
| P/B | 0.26x | KR#240/2,421 Sec#9/231 |
| P/S | 0.87x | KR#1,286/2,421 Sec#73/231 |
| EV/EBITDA | 25.20x | KR#1,119/2,421 Sec#67/231 |
| FCF Yield | -15.32% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | 4.97% | KR#1,101/2,421 Sec#77/231 |
| ROA | 3.19% | KR#1,014/2,421 Sec#78/231 |
| Op. Margin | 8.69% | KR#608/2,421 Sec#50/231 |
| Revenue Growth | 17.09% | KR#624/2,421 Sec#58/231 |
| Financial Health | ||
| Debt Ratio | 55.55% | KR#1,043/2,421 Sec#120/231 |
| Total Debt | 310.61B KRW | KR#398/2,421 Sec#21/231 |
| FCF | -28.05B KRW | KR#1,974/2,421 Sec#189/231 |
| Cash | 30.70B KRW | KR#998/2,421 Sec#67/231 |
| Current Ratio | 0.76x | KR#1,980/2,421 Sec#193/231 |
| Net Debt/EBITDA | 15.24x | KR#1,329/2,421 Sec#94/231 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | -58.30% | KR#2,183/2,421 Sec#205/231 |
| 1M Return | -18.62% | KR#2,292/2,421 Sec#207/231 |
| From 52W High | -80.76% | KR#2,352/2,421 Sec#221/231 |
| 1Y MDD | -81.21% | KR#2,318/2,421 Sec#215/231 |
| Trading | ||
| Volume | 27,257 shares | KR#1,432/2,421 Sec#141/231 |
| Trading Value | 382.9M KRW | KR#1,035/2,421 Sec#104/231 |
| Foreign Own. | 2.83% | KR#1,345/2,421 Sec#124/231 |
| Per Share | ||
| EPS | 2,645 KRW | KR#379/2,421 Sec#24/231 |
| BPS | 53,239 KRW | KR#252/2,421 Sec#15/231 |
Company Info
Kolon Life Science, established in 2000 and listed on KOSDAQ in 2009, focuses on the production of active pharmaceutical ingredients (APIs), antimicrobial agents, and bio-new drug research and development. Its pharmaceutical business supplies APIs and pharmaceutical intermediates globally, and it markets the eco-friendly antimicrobial brand Cleanbio for use in anti-dandruff shampoos and paints. The company is dedicated to cell and gene new drug development, concentrating on research and development for neuropathic pain treatments and anticancer drugs. Kolon Life Science is headquartered in Gangseo-gu, Seoul Metropolitan City.